Corpus Intelligence IC Memo — GOOD SAMARITAN HOSPITAL 2026-04-26 09:30 UTC
IC Memo — GOOD SAMARITAN HOSPITAL
Investment Committee Memorandum | FL | 333 beds | Grade C | EBITDA uplift $17.7M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

GOOD SAMARITAN HOSPITAL

CCN 100287 | PALM BEACH, FL | 333 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

GOOD SAMARITAN HOSPITAL is a 333-bed suburban community hospital in PALM BEACH, FL with $240.4M in net patient revenue and a 5.0% operating margin. The hospital serves a payer mix of 24.0% Medicare, 7.3% Medicaid, and 68.7% commercial.

Thesis: Undervalued. Our ML models identify $17.7M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 5.0% to 12.3% (+736bps).

Net Revenue HCRIS$240.4M
Current EBITDA COMPUTED$12.0M
Operating Margin COMPUTED5.0%
Occupancy HCRIS39.1%
Revenue / Bed COMPUTED$722K
Net-to-Gross HCRIS8.5%
Distress Probability ML50.4%

2. Market Context & Competitive Position

261
FL Hospitals
3.2%
State Median Margin
102
Comparable Hospitals

FL has 261 Medicare-certified hospitals with a median operating margin of 3.2%. The target's margin of 5.0% places it above the state median. Among 102 size-comparable peers (166-666 beds), the median margin is 5.5%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (166-666), prioritizing same-state peers. 102 hospitals in the comp set.

HospitalStateBedsRevenueMargin
GOOD SAMARITAN HOSPITAL (Target)FL333$240.4M5.0%
UNIVERSITY OF MIAMI HOSP & CLIFL532$2.36B0.9%
MOFFITT CANCER CENTERFL218$1.91B16.0%
MAYO CLINIC FLORIDAFL304$1.09B21.6%
ASCENSION SACRED HEART PENSACOFL559$1.04B-10.0%
MOUNT SINAI MEDICAL CENTER OF FL481$904.2M12.2%
TALLAHASSEE MEMORIAL HOSPITALFL483$871.6M-4.8%
SHANDS JACKSONVILLE MEDICAL CEFL481$861.4M-7.1%
MORTON PLANT HOSPITALFL561$773.1M7.7%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $17.7M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$5.0M+210bp18mo
Cost to Collect4.5%2.5%$4.8M+200bp12mo
Denial Rate Reduction12.0%6.5%$4.8M+198bp12mo
A/R Days Reduction5200.0%3800.0%$2.9M+122bp9mo
Clean Claim Rate88.0%96.0%$154K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$5.0M
Cost to Collect
$4.8M
Denial Rate Reduction
$4.8M
A/R Days Reduction
$2.9M
Clean Claim Rate
$154K
Total EBITDA Uplift$17.7M
Current EBITDA$12.0M
+ RCM Uplift+$17.7M
Pro Forma EBITDA$29.7M
Current Margin5.0%
Pro Forma Margin12.3%
WC Released (1x)$9.2M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$18.4M$255.8M13.90x69.3%
Base (11x exit)10.0x11.0x$18.4M$287.4M15.62x73.3%
Bull Case9.0x11.0x$16.6M$351.7M21.24x84.3%
Bull (12x exit)9.0x12.0x$16.6M$388.6M23.47x88.0%
Bear Case11.0x10.0x$20.2M$161.4M7.97x51.5%
Bear (11x exit)11.0x11.0x$20.2M$184.1M9.10x55.5%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighElevated distress probabilityModel estimates 50.4% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk
LowLow net-to-gross ratioLarge contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 102 hospitals with 166-666 beds
  • Same-state prioritization (n=103)
  • Comp margins: P25=-4.8% / P50=5.5% / P75=18.8%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.